摘要:
New intermediate compounds for preparing cephem compounds, particularly of the formula or its salt. The new intermediate compounds can be prepared by different processes, and the cephem compounds, which possess valuable pharmacological properties, can be prepared from such new intermediate compounds.
R' is an aliphatic hydrocarbon group which may have suitable substituent(s), R 2 is carboxy or protected carboxy, R 5 is hydrogen or hydroxy, X 1 and X 2 are each halogen, and the dotted line represents cepham or cephem nucleus, or a salt thereof, and processes for their preparation. The invention also relates to intermediates of the formula and their preparation and to processes for preparing known cephem-compounds and their intermediates.
摘要翻译:下式的顺式化合物:其中... R 1是可具有合适取代基的脂族烃基,R 2是羧基或被保护的羧基,R 3是氢 或羟基,X 1和X 2各自为卤素,虚线代表头孢烯或头孢烯核,或其盐,及其制备方法本发明还涉及下式的中间体: ...及其制备方法以及制备已知的cephamen化合物及其中间体的方法。
摘要:
New 3,7-disubstituted-2 or 3-cephem-4-carboxylic acid compounds of the formula: wherein
R 1 is amino or a substituted amino group; R 2 is carboxy or a protected carboxy group; the group of the formula: is di(lower)alkylamino (lower)alkylamino, a N-containing heterocyclic (lower)alkylamino group which may have suitable substituent(s), a heterocyclic group containing 2 to 4 nitrogen atoms which may have suitable substituent(s) or hydroxypiperidino; and X is -S- or e.g. 7-[2-methoxyimino-2- (2-aminothiazol-4-yl) acetamido] -3-(4-methyl-1-piperazinyl) carbonyloxymethyl-3-cephem -4-carboxylic acid (syn isomer); pharmaceutically acceptablesalts thereof; and processes for their preparation. The invention also relates to pharmaceutical compositions comprising, as an effective ingredient, the above compounds in association with a pharmaceutically acceptable; substantially nontoxic carrier or excipient; and to a process for their preparation.
摘要:
Compounds of formula (I) are used in the preparation of cephalosporins of formula (II) which are precursors of cephalosporins of formula (III) which show a pharmacological activity:
wherein:
X' = hydrogen or halogen A 1 , A 2 = acetal residue which may be linked together R, = aliphatic hydrocarbon group which may have suitable substituents Y' = carbonyl or protected carbonyl group R 2 = carboxyl or protected carboxyl group R. = hydroxy, acyloxy or methylene
摘要翻译:... ... worin ... X <1> =氢或卤:式(I)的化合物在式头孢菌素(II),其是式cephaiosporins(III),其显示具有药理活性的前体的制备中使用 ... A1,A2 =缩醛残基,其可连接在一起... R1 =可以带有合适的取代基... Y的脂肪族烃基<1> =羰基或保护的羰基... R2 =羧基或保护的羧基... R 6 =羟基,酰氧基或 亚甲基
摘要:
An antibody capable of recognizing antigenic determinant(s) located on the FR-900506 substance, a highly-sensitive enzyme immunoassay method for the FR-900506 substance, which comprises immobilizing an antibody capable of recognizing antigenic determinant(s) located on the FR-900506 substance, allowing the FR-900506 substance contained in a sample and an enzyme-labeled FR-900506 substance to react competitively with the immobilized antibody and detecting the enzyme-labeled substance bound to the immobilized antibody, and a test kit for the detection of the FR-900506 substance. The invention also comprises a process for preparation of the monoclonal antibody of claim 4, which comprises culturing a hybridoma cell line capable of producing anti-FR-900506 substance antibody and isolating it from the cultured broth.
摘要:
The invention relates to intermediates of the formula wherein R 1 is C 1 to C 6 alkyl R 4 is carboxy or protected carboxy and X 1 and X 2 are each halogen, or a salt thereof, and to processes for their preparation.
摘要翻译:下式的顺式化合物:其中... R 1是可具有合适取代基的脂族烃基,R 2是羧基或被保护的羧基,R 3是氢 或羟基,X 1和X 2各自为卤素,虚线代表头孢烯或头孢烯核,或其盐,及其制备方法本发明还涉及下式的中间体: ...及其制备方法以及制备已知的cephamen化合物及其中间体的方法。
摘要:
An antibody capable of recognizing antigenic determinant(s) located on the FR-900506 substance, a highly-sensitive enzyme immunoassay method for the FR-900506 substance, which comprises immobilizing an antibody capable of recognizing antigenic determinant(s) located on the FR-900506 substance, allowing the FR-900506 substance contained in a sample and an enzyme-labeled FR-900506 substance to react competitively with the immobilized antibody and detecting the enzyme-labeled substance bound to the immobilized antibody, and a test kit for the detection of the FR-900506 substance. The invention also comprises a process for preparation of the monoclonal antibody of claim 4, which comprises culturing a hybridoma cell line capable of producing anti-FR-900506 substance antibody and isolating it from the cultured broth.